Tags

Type your tag names separated by a space and hit enter

Q Fever Outbreak Among Travelers to Germany Who Received Live Cell Therapy--United States and Canada, 2014.
MMWR Morb Mortal Wkly Rep. 2015 Oct 02; 64(38):1071-3.MM

Abstract

During September–November 2014, the New York State Department of Health (NYSDOH) was notified of five New York state residents who had tested seropositive for Coxiella burnetii, the causative agent of Q fever. All five patients had symptoms compatible with Q fever (e.g., fever, fatigue, chills, and headache) and a history of travel to Germany to receive a medical treatment called "live cell therapy" (sometimes called "fresh cell therapy") in May 2014. Live cell therapy is the practice of injecting processed cells from organs or fetuses of nonhuman animals (e.g., sheep) into human recipients. It is advertised to treat a variety of health conditions. This practice is unavailable in the United States; however, persons can travel to foreign locations to receive injections. Local health departments interviewed the patients, and NYSDOH notified CDC and posted a report on CDC’s Epidemic Information Exchange to solicit additional cases. Clinical and exposure information for each patient was reported to the Robert Koch Institute in Germany, which forwarded the information to local health authorities. A Canada resident who also received live cell therapy in May 2014 was diagnosed with Q fever in July 2014. Clinicians should be aware of health risks, such as Q fever and other zoonotic diseases, among patients with a history of receiving treatment with live cell therapy products.

Links

  • Publisher Full Text

    • Authors

    Robyn MP
    No affiliation info available
    Newman AP
    No affiliation info available
    Amato M
    No affiliation info available
    Walawander M
    No affiliation info available
    Kothe C
    No affiliation info available
    Nerone JD
    No affiliation info available
    Pomerantz C
    No affiliation info available
    Behravesh CB
    No affiliation info available
    Biggs HM
    No affiliation info available
    Dahlgren FS
    No affiliation info available
    Pieracci EG
    No affiliation info available
    Whitfield Y
    No affiliation info available
    Sider D
    No affiliation info available
    Ozaldin O
    No affiliation info available
    Berger L
    No affiliation info available
    Buck PA
    No affiliation info available
    Downing M
    No affiliation info available
    Blog D
    No affiliation info available

    MeSH

    AgedAged, 80 and overAnimalsCanadaCell TransplantationCoxiella burnetiiDisease OutbreaksFemaleGermanyHumansMaleMedical TourismMiddle AgedNew YorkQ FeverSheepSheep DiseasesUnited StatesZoonoses

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    26421460

    Citation

    Robyn, Misha P., et al. "Q Fever Outbreak Among Travelers to Germany Who Received Live Cell Therapy--United States and Canada, 2014." MMWR. Morbidity and Mortality Weekly Report, vol. 64, no. 38, 2015, pp. 1071-3.
    Robyn MP, Newman AP, Amato M, et al. Q Fever Outbreak Among Travelers to Germany Who Received Live Cell Therapy--United States and Canada, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(38):1071-3.
    Robyn, M. P., Newman, A. P., Amato, M., Walawander, M., Kothe, C., Nerone, J. D., Pomerantz, C., Behravesh, C. B., Biggs, H. M., Dahlgren, F. S., Pieracci, E. G., Whitfield, Y., Sider, D., Ozaldin, O., Berger, L., Buck, P. A., Downing, M., & Blog, D. (2015). Q Fever Outbreak Among Travelers to Germany Who Received Live Cell Therapy--United States and Canada, 2014. MMWR. Morbidity and Mortality Weekly Report, 64(38), 1071-3. https://doi.org/10.15585/mmwr.mm6438a3
    Robyn MP, et al. Q Fever Outbreak Among Travelers to Germany Who Received Live Cell Therapy--United States and Canada, 2014. MMWR Morb Mortal Wkly Rep. 2015 Oct 2;64(38):1071-3. PubMed PMID: 26421460.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Q Fever Outbreak Among Travelers to Germany Who Received Live Cell Therapy--United States and Canada, 2014. AU - Robyn,Misha P, AU - Newman,Alexandra P, AU - Amato,Michael, AU - Walawander,Mary, AU - Kothe,Cynthia, AU - Nerone,James D, AU - Pomerantz,Cynthia, AU - Behravesh,Casey Barton, AU - Biggs,Holly M, AU - Dahlgren,F Scott, AU - Pieracci,Emily G, AU - Whitfield,Yvonne, AU - Sider,Doug, AU - Ozaldin,Omar, AU - Berger,Lisa, AU - Buck,Peter A, AU - Downing,Mark, AU - Blog,Debra, Y1 - 2015/10/02/ PY - 2015/10/1/entrez PY - 2015/10/1/pubmed PY - 2015/12/25/medline SP - 1071 EP - 3 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb. Mortal. Wkly. Rep. VL - 64 IS - 38 N2 - During September–November 2014, the New York State Department of Health (NYSDOH) was notified of five New York state residents who had tested seropositive for Coxiella burnetii, the causative agent of Q fever. All five patients had symptoms compatible with Q fever (e.g., fever, fatigue, chills, and headache) and a history of travel to Germany to receive a medical treatment called "live cell therapy" (sometimes called "fresh cell therapy") in May 2014. Live cell therapy is the practice of injecting processed cells from organs or fetuses of nonhuman animals (e.g., sheep) into human recipients. It is advertised to treat a variety of health conditions. This practice is unavailable in the United States; however, persons can travel to foreign locations to receive injections. Local health departments interviewed the patients, and NYSDOH notified CDC and posted a report on CDC’s Epidemic Information Exchange to solicit additional cases. Clinical and exposure information for each patient was reported to the Robert Koch Institute in Germany, which forwarded the information to local health authorities. A Canada resident who also received live cell therapy in May 2014 was diagnosed with Q fever in July 2014. Clinicians should be aware of health risks, such as Q fever and other zoonotic diseases, among patients with a history of receiving treatment with live cell therapy products. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/26421460/full_citation L2 - https://doi.org/10.15585/mmwr.mm6438a3 DB - PRIME DP - Unbound Medicine ER -